We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply to Bertucci, De Nonneville, and Finetti.
- Authors
Brasó-Maristany, Fara; Prat, Aleix
- Abstract
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. These data add to our previous work that reported that baseline I ERBB2 i mRNA expression is a predictor of response to neoadjuvant anti-HER2 therapy including T-DM1 ([2]) or dual anti-HER2 blockade without chemotherapy ([3],[4]). We thank Drs Bertucci, De Nonneville, and Finetti for their thoughtful correspondence in which they assess the value of I ERBB2 i mRNA expression in predicting benefit from T-DM1 plus pertuzumab (T-DM1/P) followed by doxorubicin and cyclophosphamide vs paclitaxel plus trastuzumab ± pertuzumab (TH±P) followed by doxorubicin and cyclophosphamide, in the context of the neoadjuvant I-SPY 2 trial ([1]).
- Subjects
HER2 positive breast cancer
- Publication
JNCI: Journal of the National Cancer Institute, 2023, Vol 115, Issue 6, p764
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djad059